Focus Issue: Cardiac Sympathetic Nervous System Imaging from JSNC/ASNC Joint Session in 26^th JSNC Annual Scientific Meeting

Abstract

Cardiac sympathetic dysfunction is closely associated with risk of cardiac events in heart failure (HF), indicating HF progression and sudden cardiac death by lethal ventricular arrhythmia. For cardiac sympathetic nervous system imaging, ¹²³I-meta-iodobenzylguanidine (MIBG), among other agents, has been approved by the Japanese health and welfare ministry and is widely used in clinical settings. ¹²³I-MIBG was also approved by the Food and Drug Administration (FDA) in the United States of America (USA) and is expected to achieve broad acceptance. In Europe. ¹²³I-MIBG is currently used only for clinical research. Given the current situation, the American Society of Nuclear Cardiology (ASNC) and the Japanese Society of Nuclear Cardiology (JSNC) are preparing to issue clinical guidelines for ¹²³I-MIBG imaging in Ann Nucl Cardiol.